Published in Blood on January 26, 2009
IRF8 regulates acid ceramidase expression to mediate apoptosis and suppresses myelogeneous leukemia. Cancer Res (2011) 1.05
Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells. PLoS One (2013) 0.88
Cross talk between Wnt/β-catenin and Irf8 in leukemia progression and drug resistance. J Exp Med (2013) 0.85
Mammary gland morphological and gene expression changes underlying pregnancy protection of breast cancer tumorigenesis. Physiol Genomics (2011) 0.81
Constitutive IRF8 expression inhibits AML by activation of repressed immune response signaling. Leukemia (2014) 0.80
Batf3 and Id2 have a synergistic effect on Irf8-directed classical CD8α+ dendritic cell development. J Immunol (2013) 0.79
Tyrosine kinase chromosomal translocations mediate distinct and overlapping gene regulation events. BMC Cancer (2011) 0.76
Cellular intrinsic mechanism affecting the outcome of AML treated with Ara-C in a syngeneic mouse model. PLoS One (2014) 0.75
A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell (2006) 18.81
A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet (2003) 12.16
Il-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo. Cell (1985) 6.06
Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell (2003) 5.71
Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood (1995) 5.34
Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell (1996) 4.74
An interferon gamma-regulated protein that binds the interferon-inducible enhancer element of major histocompatibility complex class I genes. Proc Natl Acad Sci U S A (1990) 3.53
Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood (1990) 3.50
ICSBP is essential for the development of mouse type I interferon-producing cells and for the generation and activation of CD8alpha(+) dendritic cells. J Exp Med (2002) 2.92
Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med (2000) 2.78
Essential role for ICSBP in the in vivo development of murine CD8alpha + dendritic cells. Blood (2002) 2.77
ICSBP directs bipotential myeloid progenitor cells to differentiate into mature macrophages. Immunity (2000) 2.34
A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev (1998) 1.99
Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer (2003) 1.90
Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias. Blood (1998) 1.80
Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood (1995) 1.69
Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood (2001) 1.67
FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5/BCL6-dependent mechanism. Mol Cell Biol (2004) 1.63
Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood (1997) 1.63
CCL9 is secreted by the follicle-associated epithelium and recruits dome region Peyer's patch CD11b+ dendritic cells. J Immunol (2003) 1.54
Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-alpha. Br J Haematol (1995) 1.43
IFN consensus sequence binding protein/IFN regulatory factor-8 guides bone marrow progenitor cells toward the macrophage lineage. J Immunol (2002) 1.29
The role of interferon-alpha in the treatment of chronic myeloid leukemia. Cytokine Growth Factor Rev (2007) 1.29
Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2. Blood (2003) 1.22
Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol (2002) 1.18
The SH2 domain of P210BCR/ABL is not required for the transformation of hematopoietic factor-dependent cells. Blood (1995) 1.15
The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance. Leukemia (2006) 1.15
Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells. Oncogene (2001) 1.13
ICSBP/IRF-8 inhibits mitogenic activity of p210 Bcr/Abl in differentiating myeloid progenitor cells. Blood (2003) 1.09
The interferon regulatory factor ICSBP/IRF-8 in combination with PU.1 up-regulates expression of tumor suppressor p15(Ink4b) in murine myeloid cells. Blood (2004) 1.09
The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine model. Oncogene (2002) 1.05
The chemokine CCL6 promotes innate immunity via immune cell activation and recruitment. J Immunol (2007) 1.03
Association of natural killer cell immune recovery with a graft-versus-leukemia effect independent of graft-versus-host disease following allogeneic bone marrow transplantation. Ann Hematol (1997) 1.01
Immunotherapy of hematologic malignancy. Hematology Am Soc Hematol Educ Program (2003) 1.00
Expression of interferon consensus sequence binding protein induces potent immunity against BCR/ABL-induced leukemia. Blood (2001) 1.00
A screen to identify drug resistant variants to target-directed anti-cancer agents. Biol Proced Online (2003) 0.99
The graft-versus-leukemia effects of allogeneic cell therapy. Annu Rev Med (1999) 0.96
Molecular cloning and functional characterization of a novel member of the C-C chemokine family. J Immunol (1995) 0.93
Mechanisms of transformation by the BCR/ABL oncogene. Int J Hematol (2001) 0.85
Adoptive immunotherapy of BCR-ABL-induced chronic myeloid leukemia-like myeloproliferative disease in a murine model. Blood (2004) 0.84
Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy. Blood (1992) 0.84
Immunological effects of interferon-alpha on chronic myelogenous leukemia. Leuk Lymphoma (2003) 0.82
Expression of CCL9/MIP-1gamma is repressed by BCR/ABL and its restoration suppresses in vivo leukemogenesis of 32D-BCR/ABL cells. Oncogene (2006) 0.79
Relative roles of natural killer- and T cell-mediated anti-leukemia effects in chronic myelogenous leukemia patients treated with interferon-alpha. Leuk Lymphoma (1995) 0.79
Unrelated donor leukocyte infusions to treat relapse after unrelated donor bone marrow transplantation. Leuk Lymphoma (2002) 0.76
Reprogramming of human somatic cells to pluripotency with defined factors. Nature (2007) 30.84
Disease-specific induced pluripotent stem cells. Cell (2008) 16.95
Selective blockade of microRNA processing by Lin28. Science (2008) 14.39
Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell (2010) 14.18
Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. Nat Biotechnol (2009) 11.18
Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet (2009) 10.54
Somatic coding mutations in human induced pluripotent stem cells. Nature (2011) 9.50
Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. Cell Stem Cell (2009) 8.97
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell (2005) 7.99
Targeted bisulfite sequencing reveals changes in DNA methylation associated with nuclear reprogramming. Nat Biotechnol (2009) 7.59
Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature (2007) 7.55
Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells. Nature (2011) 7.43
Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells. Cell Stem Cell (2011) 7.41
Live cell imaging distinguishes bona fide human iPS cells from partially reprogrammed cells. Nat Biotechnol (2009) 6.76
Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet (2009) 6.35
Comprehensive methylome map of lineage commitment from haematopoietic progenitors. Nature (2010) 6.06
HoxB4 confers definitive lymphoid-myeloid engraftment potential on embryonic stem cell and yolk sac hematopoietic progenitors. Cell (2002) 5.71
Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell (2003) 5.71
Large intergenic non-coding RNA-RoR modulates reprogramming of human induced pluripotent stem cells. Nat Genet (2010) 5.37
The promise of induced pluripotent stem cells in research and therapy. Nature (2012) 5.05
Generation of induced pluripotent stem cells from human blood. Blood (2009) 4.92
Generation of human-induced pluripotent stem cells. Nat Protoc (2008) 4.85
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration. Cell (2009) 4.69
The Lin28/let-7 axis regulates glucose metabolism. Cell (2011) 4.65
Derivation of embryonic germ cells and male gametes from embryonic stem cells. Nature (2003) 4.56
Correction of a genetic defect by nuclear transplantation and combined cell and gene therapy. Cell (2002) 4.56
Determinants of microRNA processing inhibition by the developmentally regulated RNA-binding protein Lin28. J Biol Chem (2008) 4.40
Chromatin-modifying enzymes as modulators of reprogramming. Nature (2012) 4.22
Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. Nature (2009) 4.14
Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. Nat Biotechnol (2011) 3.97
Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature (2009) 3.93
Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature (2010) 3.39
Lin28: A microRNA regulator with a macro role. Cell (2010) 3.39
Generation of functional human hepatic endoderm from human induced pluripotent stem cells. Hepatology (2010) 3.36
Donor cell type can influence the epigenome and differentiation potential of human induced pluripotent stem cells. Nat Biotechnol (2011) 3.25
Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol (2008) 3.18
Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells. Cell Stem Cell (2010) 3.08
Lin28 enhances tissue repair by reprogramming cellular metabolism. Cell (2013) 3.08
Broader implications of defining standards for the pluripotency of iPSCs. Cell Stem Cell (2009) 3.03
Biomechanical forces promote embryonic haematopoiesis. Nature (2009) 2.99
Influence of threonine metabolism on S-adenosylmethionine and histone methylation. Science (2012) 2.98
Metabolic regulation of protein N-alpha-acetylation by Bcl-xL promotes cell survival. Cell (2011) 2.98
Reprogramming of T cells from human peripheral blood. Cell Stem Cell (2010) 2.93
A role for Lin28 in primordial germ-cell development and germ-cell malignancy. Nature (2009) 2.88
Transplantation of adult mouse iPS cell-derived photoreceptor precursors restores retinal structure and function in degenerative mice. PLoS One (2011) 2.86
Stage-specific signaling through TGFβ family members and WNT regulates patterning and pancreatic specification of human pluripotent stem cells. Development (2011) 2.82
A robust approach to identifying tissue-specific gene expression regulatory variants using personalized human induced pluripotent stem cells. PLoS Genet (2009) 2.78
High-efficiency RNA interference in human embryonic stem cells. Stem Cells (2005) 2.76
Lin28a transgenic mice manifest size and puberty phenotypes identified in human genetic association studies. Nat Genet (2010) 2.72
Midbody accumulation through evasion of autophagy contributes to cellular reprogramming and tumorigenicity. Nat Cell Biol (2011) 2.65
New ISSCR guidelines underscore major principles for responsible translational stem cell research. Cell Stem Cell (2008) 2.61
Functional evidence that the self-renewal gene NANOG regulates human tumor development. Stem Cells (2009) 2.59
Induced pluripotent stem cells--opportunities for disease modelling and drug discovery. Nat Rev Drug Discov (2011) 2.58
Teratoma formation assays with human embryonic stem cells: a rationale for one type of human-animal chimera. Cell Stem Cell (2007) 2.56
Lineage regulators direct BMP and Wnt pathways to cell-specific programs during differentiation and regeneration. Cell (2011) 2.53
Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med (2010) 2.50
LIF/STAT3 signaling fails to maintain self-renewal of human embryonic stem cells. Stem Cells (2004) 2.37
Telomere elongation in induced pluripotent stem cells from dyskeratosis congenita patients. Nature (2010) 2.36
Impaired intrinsic immunity to HSV-1 in human iPSC-derived TLR3-deficient CNS cells. Nature (2012) 2.32
Embryonic stem cell-derived hematopoietic stem cells. Proc Natl Acad Sci U S A (2005) 2.28
Lin28: primal regulator of growth and metabolism in stem cells. Cell Stem Cell (2013) 2.27
BMP and Wnt specify hematopoietic fate by activation of the Cdx-Hox pathway. Cell Stem Cell (2008) 2.17
cdx4 mutants fail to specify blood progenitors and can be rescued by multiple hox genes. Nature (2003) 2.16
Recombination signatures distinguish embryonic stem cells derived by parthenogenesis and somatic cell nuclear transfer. Cell Stem Cell (2007) 2.14
Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability. Proc Natl Acad Sci U S A (2012) 2.14
Overcoming reprogramming resistance of Fanconi anemia cells. Blood (2012) 2.07
Polycomb repressive complex 2 regulates normal development of the mouse heart. Circ Res (2011) 2.05
Stem cell metabolism in tissue development and aging. Development (2013) 2.01
The transcriptional landscape of hematopoietic stem cell ontogeny. Cell Stem Cell (2012) 1.96
Therapeutic potential of embryonic stem cells. Blood Rev (2005) 1.96
Origins and implications of pluripotent stem cell variability and heterogeneity. Nat Rev Mol Cell Biol (2013) 1.91
Metabolic regulation in pluripotent stem cells during reprogramming and self-renewal. Cell Stem Cell (2012) 1.89
Knockdown of Fanconi anemia genes in human embryonic stem cells reveals early developmental defects in the hematopoietic lineage. Blood (2010) 1.88
Lin28 sustains early renal progenitors and induces Wilms tumor. Genes Dev (2014) 1.87
Efficiency of embryoid body formation and hematopoietic development from embryonic stem cells in different culture systems. Biotechnol Bioeng (2002) 1.85
Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol (2004) 1.83
Robust enhancement of neural differentiation from human ES and iPS cells regardless of their innate difference in differentiation propensity. Stem Cell Rev (2010) 1.77
Altered nuclear transfer in stem-cell research - a flawed proposal. N Engl J Med (2004) 1.77
Upping the ante: recent advances in direct reprogramming. Mol Ther (2009) 1.73
Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood (2002) 1.72
Induced pluripotent stem cell models from X-linked adrenoleukodystrophy patients. Ann Neurol (2011) 1.72
Reprogramming cellular identity for regenerative medicine. Cell (2012) 1.71
Modulation of murine embryonic stem cell-derived CD41+c-kit+ hematopoietic progenitors by ectopic expression of Cdx genes. Blood (2008) 1.71
Induction of multipotential hematopoietic progenitors from human pluripotent stem cells via respecification of lineage-restricted precursors. Cell Stem Cell (2013) 1.68
A senescence rescue screen identifies BCL6 as an inhibitor of anti-proliferative p19(ARF)-p53 signaling. Genes Dev (2002) 1.65
Induced pluripotent stem cells: a novel frontier in the study of human primary immunodeficiencies. J Allergy Clin Immunol (2010) 1.65
Functional vascular smooth muscle cells derived from human induced pluripotent stem cells via mesenchymal stem cell intermediates. Cardiovasc Res (2012) 1.65
The May-Hegglin anomaly gene MYH9 is a negative regulator of platelet biogenesis modulated by the Rho-ROCK pathway. Blood (2007) 1.64
Altered hematopoiesis in trisomy 21 as revealed through in vitro differentiation of isogenic human pluripotent cells. Proc Natl Acad Sci U S A (2012) 1.62
Human embryonic stem cell derivation from poor-quality embryos. Nat Biotechnol (2008) 1.60
Novel role for PDEF in epithelial cell migration and invasion. Cancer Res (2005) 1.57